company background image
RMDA

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)ECASE:RMDA Stock Report

Market Cap

ج.م1.8b

7D

-3.2%

1Y

-31.4%

Updated

25 Oct, 2021

Data

Company Financials +
RMDA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance2/6
Financial Health4/6
Dividends0/6

RMDA Overview

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals and nutraceuticals in Egypt.

Price History & Performance

Summary of all time highs, changes and price drops for Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E
Historical stock prices
Current Share Priceج.م1.83
52 Week Highج.م1.65
52 Week Lowج.م3.18
Beta0
1 Month Change-13.27%
3 Month Change-13.10%
1 Year Change-31.39%
3 Year Changen/a
5 Year Changen/a
Change since IPO-46.38%

Recent News & Updates

Shareholder Returns

RMDAEG PharmaceuticalsEG Market
7D-3.2%-5.4%3.0%
1Y-31.4%-1.9%12.4%

Return vs Industry: RMDA underperformed the EG Pharmaceuticals industry which returned -0.2% over the past year.

Return vs Market: RMDA underperformed the EG Market which returned 12.2% over the past year.

Price Volatility

Is RMDA's price volatile compared to industry and market?
RMDA volatility
RMDA Beta0
Industry Beta0.84
Market Beta1

Stable Share Price: RMDA is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: RMDA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986n/aAmr Morsyhttps://www.ramedapharma.com

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals and nutraceuticals in Egypt. It manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use; and diagnostic reagents for individuals, laboratories, and hospitals. The company offers a portfolio of products in various therapeutic areas, such as anti-infective, anti-diabetic, respiratory, ophthalmology, gastrointestinal tract, cardiovascular, central nervous system, vitamins, and analgesics.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E Fundamentals Summary

How do Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E's earnings and revenue compare to its market cap?
RMDA fundamental statistics
Market Capج.م1.80b
Earnings (TTM)ج.م115.48m
Revenue (TTM)ج.م1.06b

15.8x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RMDA income statement (TTM)
Revenueج.م1.06b
Cost of Revenueج.م575.48m
Gross Profitج.م485.00m
Expensesج.م369.52m
Earningsج.م115.48m

Valuation

Is Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E undervalued compared to its fair value and its price relative to the market?

47.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RMDA (EGP1.83) is trading below our estimate of fair value (EGP3.51)

Significantly Below Fair Value: RMDA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: RMDA is poor value based on its PE Ratio (15.8x) compared to the African Pharmaceuticals industry average (15.7x).

PE vs Market: RMDA is poor value based on its PE Ratio (15.8x) compared to the EG market (8.8x).


Price to Earnings Growth Ratio

PEG Ratio: RMDA is good value based on its PEG Ratio (0.5x)


Price to Book Ratio

PB vs Industry: RMDA is good value based on its PB Ratio (1.5x) compared to the XF Pharmaceuticals industry average (2x).


Future Growth

How is Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

29.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RMDA's forecast earnings growth (29.3% per year) is above the savings rate (9.1%).

Earnings vs Market: RMDA's earnings (29.3% per year) are forecast to grow faster than the EG market (13.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RMDA's revenue (16.4% per year) is forecast to grow faster than the EG market (9.9% per year).

High Growth Revenue: RMDA's revenue (16.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RMDA's Return on Equity is forecast to be low in 3 years time (17.1%).


Past Performance

How has Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E performed over the past 5 years?

12.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RMDA has high quality earnings.

Growing Profit Margin: RMDA's current net profit margins (10.9%) are lower than last year (11.1%).


Past Earnings Growth Analysis

Earnings Trend: RMDA's earnings have grown by 12.8% per year over the past 5 years.

Accelerating Growth: RMDA's earnings growth over the past year (9.8%) is below its 5-year average (12.8% per year).

Earnings vs Industry: RMDA earnings growth over the past year (9.8%) underperformed the Pharmaceuticals industry 10%.


Return on Equity

High ROE: RMDA's Return on Equity (10.5%) is considered low.


Financial Health

How is Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E's financial position?


Financial Position Analysis

Short Term Liabilities: RMDA's short term assets (EGP1.4B) exceed its short term liabilities (EGP899.5M).

Long Term Liabilities: RMDA's short term assets (EGP1.4B) exceed its long term liabilities (EGP50.0M).


Debt to Equity History and Analysis

Debt Level: RMDA's debt to equity ratio (63.9%) is considered high.

Reducing Debt: RMDA's debt to equity ratio has reduced from 111.8% to 63.9% over the past 5 years.

Debt Coverage: RMDA's debt is not well covered by operating cash flow (11.1%).

Interest Coverage: RMDA's interest payments on its debt are well covered by EBIT (6.4x coverage).


Balance Sheet


Dividend

What is Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RMDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RMDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RMDA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RMDA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RMDA's dividend in 3 years as they are not forecast to pay a notable one for the EG market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Amr Morsy

no data

Tenure

Dr. Amr Abdallah Morsy serves as Chief Executive Officer at Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (formerly known as Rameda Pharmaceutical). Prior to joining Ramed...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.'s employee growth, exchange listings and data sources


Key Information

  • Name: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
  • Ticker: RMDA
  • Exchange: CASE
  • Founded: 1986
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م1.800b
  • Shares outstanding: 1.00b
  • Website: https://www.ramedapharma.com

Location

  • Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
  • Second Industrial Zone
  • Plot number 5
  • 6th of October City
  • Egypt

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 16:54
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.